Watson settles with Janssen over Ortho Tri-Cyclen LO

8 February 2012

US generic drugmaker Watson Pharmaceutical (NYSE: WPI) says that its subsidiary, Watson Laboratories, has reached a settlement with Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals (formerly Ortho-McNeil-Janssen Pharmaceuticals) on outstanding patent litigation related to Watson's generic version of Janssen's oral contraceptive Ortho Tri-Cyclen LO (norgestimate/ethinyl estradiol) tablets.

Janssen filed its law suit on October 16, 2008 in the US District Court for the District of New Jersey following Watson's filing of an Abbreviated New Drug Application with the US Food and Drug Administration seeking approval to market its product prior to the expiration of US Patent No 6,241,815.

Janssen will manufacture the product for Watson

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK